Latest Breaking News On - Aimmax therapeutics inc - Page 1 : comparemela.com

APP13007 Emerging Drug Insights And Market Forecasts, 2019-2032: Focus On United States, Germany, France, Italy, Spain, United Kingdom, Canada And Sou

APP13007 Emerging Drug Insights And Market Forecasts, 2019-2032: Focus On United States, Germany, France, Italy, Spain, United Kingdom, Canada And Sou
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited kingdomUnited statesLaura woodE st office hours callClinical developmentFormosa pharmaceuticals incActivus pure nanoparticle technologyOffice hours callAimmax therapeutics incDrug insightMarket forecastFormosa pharmaceuticalsAimmax therapeuticsTopics coveredMarketed therapies

APP13007 Emerging Drug Insights and Market Forecasts, 2019-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, Canada and South Korea

/PRNewswire/ The "APP13007 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com s offering. This report.

United statesSouth koreaUnited kingdomLaura woodAimmax therapeutics incE st office hours callFormosa pharmaceuticals incOffice hours callActivus pure nanoparticle technologyClinical developmentDrug insightMarket forecastFormosa pharmaceuticalsAimmax therapeuticsTopics coveredMarketed therapies

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

/PRNewswire/ Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the.

United statesT ai peiFormosa pharmaceuticals incUnited states food drug administrationFormosa pharmaceuticalsAimmax therapeutics incAimmax therapeuticsNew drug applicationUnited states foodDrug administrationMax therapeuticsFormosa pharmaceuticals inc

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery

/PRNewswire/ Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the.

T ai peiUnited statesDerek nunezLaurene wangFormosa pharmaAimmax therapeutics incFormosa pharmaceuticals incMerick coFormosa pharmaceuticalsPrnewswire formosa pharmaceuticals incAimmax therapeuticsAimmax therapeutic chief medical officerAimmax therapeutic chief executive officerFormosa pharmaceutical chief executiveFormosa pharmaceuticalMax therapeutics

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

/PRNewswire/ Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the.

United statesNorth carolinaResearch triangle parkAimmax therapeutics incFormosa pharmaceuticalsAimmax therapeuticsMax therapeuticsFormosa pharmaceuticals inc